Oncology 04/2017 First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640 AACR Annual Meeting Graviton Love6
Oncology 09/2016 Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients Precison: Lung Cancer R&D Summit natalia Love6
Oncology 03/2016 Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 International Congress on Targeted Anticancer Therapies Graviton Love4
Oncology 02/2016 Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement Keystone Symposium - New Frontiers in Understanding Tumor Metabolism Graviton Love4
Oncology 11/2014 Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 EORTC-NCI-AACR International Conference natalia Love4
Virology 11/2012 Potent HCV Antiviral Activity by Inhibiting Fatty Acid Synthase AASLD The Liver Meeting natalia Love4